CD19 and B-cell chronic lymphocytic leukemia: In patients with CLL, Fraietta et al. found that those achieving CR received lower percentages of anti-CD19 CAR-T cells expressing PD-1 combined with either TIM3 or LAG3, compared with patients achieving partial or no response.